Do analysts rate FEMY or HSAQ?

Femasys presently has a consensus target price of $50.00, indicating a potential upside of 2,740.91%. Given Femasys' stronger consensus rating and higher possible upside, research analysts plainly believe Femasys is more favorable than Health Sciences Acquisitions Co. 2. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, FEMY or HSAQ?

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Femasys. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.29M 6.44 -$18.63M -$3.53 N/A Health Sciences Acquisitions Co. 2 N/A N/A -$380K N/A N/A

Which has higher earnings & valuation, RNXT or FEMY?

RenovoRx has higher earnings, but lower revenue than Femasys. RenovoRx is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RenovoRx $1.12M 46.34 -$11.17M -$0.31 N/A Femasys $2.29M 6.44 -$18.63M -$3.53 N/A

Is RNXT or FEMY more profitable?

Femasys has a net margin of -534.36% compared to RenovoRx's net margin of -621.71%. RenovoRx's return on equity of -135.11% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets RenovoRx -621.71% -135.11% -101.91% Femasys -534.36% -225.97% -74.68%

Does the media favor RNXT or FEMY?

In the previous week, RenovoRx and RenovoRx both had 4 articles in the media. Femasys' average media sentiment score of 0.45 beat RenovoRx's score of -0.21 indicating that Femasys is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Femasys 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend DXR or FEMY?

Femasys has a consensus price target of $50.00, indicating a potential upside of 2,740.91%. Given Femasys' higher probable upside, analysts plainly believe Femasys is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher earnings & valuation, DXR or FEMY?

Daxor has higher earnings, but lower revenue than Femasys. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Daxor N/A N/A N/A N/A N/A Femasys $2.29M 6.44 -$18.63M -$3.53 N/A

Is DXR or FEMY more profitable?

Daxor has a net margin of 0.00% compared to Femasys' net margin of -534.36%. Daxor's return on equity of 0.00% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Daxor N/A N/A N/A Femasys -534.36% -225.97% -74.68%

Does the media favor DXR or FEMY?

In the previous week, Daxor had 1 more articles in the media than Femasys. MarketBeat recorded 5 mentions for Daxor and 4 mentions for Femasys. Femasys' average media sentiment score of 0.45 beat Daxor's score of 0.33 indicating that Femasys is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Daxor 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Femasys 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer FEMY or QTEX?

Femasys presently has a consensus price target of $50.00, indicating a potential upside of 2,740.91%. Given Femasys' stronger consensus rating and higher probable upside, research analysts clearly believe Femasys is more favorable than Inspira Technologies OXY B.H.N.. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Inspira Technologies OXY B.H.N. 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, FEMY or QTEX?

Inspira Technologies OXY B.H.N. has lower revenue, but higher earnings than Femasys. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.29M 6.44 -$18.63M -$3.53 N/A Inspira Technologies OXY B.H.N. $290K 195.87 -$13.22M N/A N/A

Does the media prefer FEMY or QTEX?

In the previous week, Inspira Technologies OXY B.H.N. had 4 more articles in the media than Femasys. MarketBeat recorded 8 mentions for Inspira Technologies OXY B.H.N. and 4 mentions for Femasys. Inspira Technologies OXY B.H.N.'s average media sentiment score of 1.19 beat Femasys' score of 0.45 indicating that Inspira Technologies OXY B.H.N. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inspira Technologies OXY B.H.N. 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, FEMY or NYXH?

Femasys has higher earnings, but lower revenue than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.29M 6.44 -$18.63M -$3.53 N/A Nyxoah $11.33M 4.38 -$101.92M -$2.52 N/A

Is FEMY or NYXH more profitable?

Nyxoah has a net margin of -443.16% compared to Femasys' net margin of -534.36%. Nyxoah's return on equity of -178.90% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -534.36% -225.97% -74.68% Nyxoah -443.16% -178.90% -81.83%

Femasys (FEMY) Competitors

$1.65 -0.11 (-6.25%)

As of 11:18 AM Eastern

Compare

FEMY vs. HSAQ, RNXT, DXR, QTEX, and NYXH

Should you buy Femasys stock or one of its competitors? Femasys's main competitors and comparable companies include Health Sciences Acquisitions Co. 2 (HSAQ), RenovoRx (RNXT), Daxor (DXR), Inspira Technologies OXY B.H.N. (QTEX), and Nyxoah (NYXH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Femasys compare to Health Sciences Acquisitions Co. 2?

Femasys (NASDAQ:FEMY) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Femasys has a beta of -2.16, indicating that its share price is 316% less volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

65.3% of Femasys shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 7.8% of Femasys shares are owned by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Femasys' net margin of -534.36%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-225.97%	-74.68%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

Femasys presently has a consensus target price of $50.00, indicating a potential upside of 2,740.91%. Given Femasys' stronger consensus rating and higher possible upside, research analysts plainly believe Femasys is more favorable than Health Sciences Acquisitions Co. 2.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Health Sciences Acquisitions Co. 2	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Femasys.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	6.44	-$18.63M	-$3.53	N/A
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380K	N/A	N/A

In the previous week, Femasys had 4 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 4 mentions for Femasys and 0 mentions for Health Sciences Acquisitions Co. 2. Femasys' average media sentiment score of 0.45 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Femasys is being referred to more favorably in the media.

Company	Overall Sentiment
Femasys	Neutral
Health Sciences Acquisitions Co. 2	Neutral

Summary

Health Sciences Acquisitions Co. 2 beats Femasys on 7 of the 13 factors compared between the two stocks.

How does Femasys compare to RenovoRx?

RenovoRx (NASDAQ:RNXT) and Femasys (NASDAQ:FEMY) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

RenovoRx has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Femasys has a beta of -2.16, indicating that its stock price is 316% less volatile than the broader market.

In the previous week, RenovoRx and RenovoRx both had 4 articles in the media. Femasys' average media sentiment score of 0.45 beat RenovoRx's score of -0.21 indicating that Femasys is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by insiders. Comparatively, 7.8% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

RenovoRx currently has a consensus price target of $8.50, indicating a potential upside of 639.13%. Femasys has a consensus price target of $50.00, indicating a potential upside of 2,740.91%. Given Femasys' higher probable upside, analysts plainly believe Femasys is more favorable than RenovoRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

RenovoRx has higher earnings, but lower revenue than Femasys. RenovoRx is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	46.34	-$11.17M	-$0.31	N/A
Femasys	$2.29M	6.44	-$18.63M	-$3.53	N/A

Femasys has a net margin of -534.36% compared to RenovoRx's net margin of -621.71%. RenovoRx's return on equity of -135.11% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-621.71%	-135.11%	-101.91%
Femasys	-534.36%	-225.97%	-74.68%

Summary

RenovoRx beats Femasys on 8 of the 15 factors compared between the two stocks.

How does Femasys compare to Daxor?

Daxor (NASDAQ:DXR) and Femasys (NASDAQ:FEMY) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

1.3% of Daxor shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 51.5% of Daxor shares are owned by insiders. Comparatively, 7.8% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Daxor had 1 more articles in the media than Femasys. MarketBeat recorded 5 mentions for Daxor and 4 mentions for Femasys. Femasys' average media sentiment score of 0.45 beat Daxor's score of 0.33 indicating that Femasys is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Daxor	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Daxor has higher earnings, but lower revenue than Femasys.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
Femasys	$2.29M	6.44	-$18.63M	-$3.53	N/A

Femasys has a consensus price target of $50.00, indicating a potential upside of 2,740.91%. Given Femasys' higher probable upside, analysts plainly believe Femasys is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Daxor has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Femasys has a beta of -2.16, indicating that its stock price is 316% less volatile than the broader market.

Daxor has a net margin of 0.00% compared to Femasys' net margin of -534.36%. Daxor's return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Femasys	-534.36%	-225.97%	-74.68%

Summary

Daxor beats Femasys on 6 of the 11 factors compared between the two stocks.

How does Femasys compare to Inspira Technologies OXY B.H.N.?

Femasys (NASDAQ:FEMY) and Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

65.3% of Femasys shares are held by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. 7.8% of Femasys shares are held by company insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Inspira Technologies OXY B.H.N. has a net margin of 0.00% compared to Femasys' net margin of -534.36%. Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-225.97%	-74.68%
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A

In the previous week, Inspira Technologies OXY B.H.N. had 4 more articles in the media than Femasys. MarketBeat recorded 8 mentions for Inspira Technologies OXY B.H.N. and 4 mentions for Femasys. Inspira Technologies OXY B.H.N.'s average media sentiment score of 1.19 beat Femasys' score of 0.45 indicating that Inspira Technologies OXY B.H.N. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inspira Technologies OXY B.H.N.	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inspira Technologies OXY B.H.N. has lower revenue, but higher earnings than Femasys.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	6.44	-$18.63M	-$3.53	N/A
Inspira Technologies OXY B.H.N.	$290K	195.87	-$13.22M	N/A	N/A

Femasys presently has a consensus price target of $50.00, indicating a potential upside of 2,740.91%. Given Femasys' stronger consensus rating and higher probable upside, research analysts clearly believe Femasys is more favorable than Inspira Technologies OXY B.H.N..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Femasys has a beta of -2.16, suggesting that its stock price is 316% less volatile than the broader market. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 4.23, suggesting that its stock price is 323% more volatile than the broader market.

Summary

Inspira Technologies OXY B.H.N. beats Femasys on 9 of the 14 factors compared between the two stocks.

How does Femasys compare to Nyxoah?

Femasys (NASDAQ:FEMY) and Nyxoah (NASDAQ:NYXH) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

Femasys has higher earnings, but lower revenue than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	6.44	-$18.63M	-$3.53	N/A
Nyxoah	$11.33M	4.38	-$101.92M	-$2.52	N/A

Femasys has a beta of -2.16, meaning that its share price is 316% less volatile than the broader market. Comparatively, Nyxoah has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

65.3% of Femasys shares are owned by institutional investors. 7.8% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nyxoah has a net margin of -443.16% compared to Femasys' net margin of -534.36%. Nyxoah's return on equity of -178.90% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-225.97%	-74.68%
Nyxoah	-443.16%	-178.90%	-81.83%

Femasys presently has a consensus price target of $50.00, suggesting a potential upside of 2,740.91%. Nyxoah has a consensus price target of $4.26, suggesting a potential upside of 232.97%. Given Femasys' stronger consensus rating and higher possible upside, analysts plainly believe Femasys is more favorable than Nyxoah.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Femasys had 3 more articles in the media than Nyxoah. MarketBeat recorded 4 mentions for Femasys and 1 mentions for Nyxoah. Nyxoah's average media sentiment score of 1.82 beat Femasys' score of 0.45 indicating that Nyxoah is being referred to more favorably in the news media.

Company	Overall Sentiment
Femasys	Neutral
Nyxoah	Very Positive

Summary

Femasys beats Nyxoah on 10 of the 16 factors compared between the two stocks.

Get Femasys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FEMY vs. The Competition

Export

Metric	Femasys	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.20M	$5.52B	$7.25B	$13.04B
Dividend Yield	N/A	1.75%	2.52%	22.89%
P/E Ratio	-0.48	25.48	275.44	25.51
Price / Sales	6.20	66.54	562.05	79.58
Price / Cash	N/A	32.25	77.16	53.04
Price / Book	0.84	5.81	10.64	6.00
Net Income	-$18.63M	$146.14M	$3.49B	$380.50M
7 Day Performance	-15.25%	-1.66%	-3.21%	-3.35%
1 Month Performance	-36.52%	-4.35%	-7.65%	-6.23%
1 Year Performance	-85.63%	0.80%	2.92%	-3.96%

Femasys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FEMY Femasys	3.8236 of 5 stars	$1.65 -6.3%	$50.00 +2,930.3%	-83.5%	$13.83M	$2.29M	N/A	54	News Coverage
HSAQ Health Sciences Acquisitions Co. 2	N/A	$6.03 +1.3%	N/A	+87.6%	$67.61M	N/A	N/A	4
RNXT RenovoRx	2.2023 of 5 stars	$1.39 -5.4%	$8.50 +511.5%	+6.5%	$62.73M	$1.12M	N/A	17	Gap Up
DXR Daxor	1.3831 of 5 stars	$10.30 -3.1%	N/A	-19.6%	$60.13M	$8.15M	N/A	37	News Coverage Short Interest Increase
QTEX Inspira Technologies OXY B.H.N.	1.5581 of 5 stars	$1.59 +3.2%	N/A	N/A	$57.16M	$290K	N/A	41	News Coverage Positive News Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FEMY) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Femasys (FEMY) Competitors

FEMY vs. HSAQ, RNXT, DXR, QTEX, and NYXH

How does Femasys compare to Health Sciences Acquisitions Co. 2?

Summary

How does Femasys compare to RenovoRx?

Summary

How does Femasys compare to Daxor?

Summary

How does Femasys compare to Inspira Technologies OXY B.H.N.?

Summary

How does Femasys compare to Nyxoah?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEMY vs. The Competition

Femasys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Femasys (FEMY) Competitors

FEMY vs. HSAQ, RNXT, DXR, QTEX, and NYXH

How does Femasys compare to Health Sciences Acquisitions Co. 2?

Which has more volatility & risk, FEMY or HSAQ?

Do insiders and institutionals have more ownership in FEMY or HSAQ?

Is FEMY or HSAQ more profitable?

Do analysts rate FEMY or HSAQ?

Which has better valuation and earnings, FEMY or HSAQ?

Does the media prefer FEMY or HSAQ?

Summary

How does Femasys compare to RenovoRx?

Which has more risk & volatility, RNXT or FEMY?

Does the media favor RNXT or FEMY?

Do insiders and institutionals believe in RNXT or FEMY?

Do analysts recommend RNXT or FEMY?

Which has higher earnings & valuation, RNXT or FEMY?

Is RNXT or FEMY more profitable?

Summary

How does Femasys compare to Daxor?

Do insiders and institutionals believe in DXR or FEMY?

Does the media favor DXR or FEMY?

Which has higher earnings & valuation, DXR or FEMY?

Do analysts recommend DXR or FEMY?

Which has more risk & volatility, DXR or FEMY?

Is DXR or FEMY more profitable?

Summary

How does Femasys compare to Inspira Technologies OXY B.H.N.?

Do institutionals and insiders have more ownership in FEMY or QTEX?

Is FEMY or QTEX more profitable?

Does the media prefer FEMY or QTEX?

Which has higher valuation and earnings, FEMY or QTEX?

Do analysts prefer FEMY or QTEX?

Which has more risk and volatility, FEMY or QTEX?

Summary

How does Femasys compare to Nyxoah?

Which has preferable earnings and valuation, FEMY or NYXH?

Which has more volatility and risk, FEMY or NYXH?

Do insiders and institutionals hold more shares of FEMY or NYXH?

Is FEMY or NYXH more profitable?

Do analysts prefer FEMY or NYXH?

Does the media prefer FEMY or NYXH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEMY vs. The Competition

Femasys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools